- Home
- SGMO vs LUCD Comparison
SGMO vs LUCD Comparison
Compare SGMO & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- LUCD
- Stock Information
- Founded
- SGMO 1995
- LUCD 2018
- Country
- SGMO United States
- LUCD United States
- Employees
- SGMO N/A
- LUCD N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SGMO Health Care
- LUCD Health Care
- Exchange
- SGMO Nasdaq
- LUCD Nasdaq
- Market Cap
- SGMO 122.8M
- LUCD 112.5M
- IPO Year
- SGMO 2000
- LUCD 2021
- Fundamental
- Price
- SGMO $0.59
- LUCD $1.11
- Analyst Decision
- SGMO Buy
- LUCD Strong Buy
- Analyst Count
- SGMO 6
- LUCD 4
- Target Price
- SGMO $4.50
- LUCD $3.94
- AVG Volume (30 Days)
- SGMO 5.2M
- LUCD 1.5M
- Earning Date
- SGMO 08-05-2025
- LUCD 08-11-2025
- Dividend Yield
- SGMO N/A
- LUCD N/A
- EPS Growth
- SGMO N/A
- LUCD N/A
- EPS
- SGMO N/A
- LUCD N/A
- Revenue
- SGMO $63,756,000.00
- LUCD $4,173,000.00
- Revenue This Year
- SGMO $1.29
- LUCD $49.70
- Revenue Next Year
- SGMO $1.60
- LUCD $198.20
- P/E Ratio
- SGMO N/A
- LUCD N/A
- Revenue Growth
- SGMO 239.92
- LUCD 39.89
- 52 Week Low
- SGMO $0.41
- LUCD $0.72
- 52 Week High
- SGMO $3.18
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- SGMO 60.91
- LUCD 44.54
- Support Level
- SGMO $0.50
- LUCD $1.08
- Resistance Level
- SGMO $0.65
- LUCD $1.14
- Average True Range (ATR)
- SGMO 0.04
- LUCD 0.07
- MACD
- SGMO 0.01
- LUCD 0.00
- Stochastic Oscillator
- SGMO 64.22
- LUCD 41.03
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.